Description
A PDE5A inhibitor (IC50 = 574 nM) that prevents platelet aggregation by increasing cGMP levels and blocking the reuptake of adenosine via red blood cells; scavenges the free radicals that inactivate COX, leading to the inhibition of platelet activation and thrombin generation; also inhibits PDE11A (IC50 = 370 nM) and ENT1 (Ki = 8.18 nM); inhibits replication of SARS-CoV-2 in Vero E6 cells at 100 nM
Formal name: 2,2’,2”,2”’-[(4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetrakis-ethanol
Synonyms: NSC 515776|NSC 619103
Molecular weight: 504.6
CAS: 58-32-2
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Small Molecule Inhibitors|Phosphodiesterases||Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Cardiovascular Diseases|Stroke||Research Area|Cell Biology|Cell Signaling|cAMP Signaling||Research Area|Cell Biology|Cell Signaling|cGMP Signaling||Research Area|Cell Biology|Proteolysis|Cytosolic & Secreted Proteases||Research Area|Immunology & Inflammation|Pulmonary Diseases|COVID-19||Research Area|Infectious Disease|Viral Diseases|Coronaviruses